ReviewAging2019
Can ovarian aging be delayed by pharmacological strategies?
Review in Aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of hysterectomy on ovarian function: a systematic review and meta-analysis.Journal of ovarian research · 2023Pooled it
- Whole-grain black rice diet rewires the single-cell transcriptomic landscape of age-related ovarian decline in mice.Science China. Life sciences · 2026Article
- Reproductive Longevity: Innovative Approaches Beyond Hormone Replacement Therapy.Medicina (Kaunas, Lithuania) · 2026Review
- Research Hotspots and Emerging Frontiers in Ovarian Aging: A Bibliometric Analysis (2006-2025).Endocrine, metabolic & immune disorders drug targets · 2026Review
- Preventing ovarian aging: from redox-targeted strategies to extracellular vesicle-based therapies.Frontiers in aging · 2026Review
- Review
- Thymol Mitigates Oxidative Stress-Induced Ovarian Aging and Restores Steroidogenesis via the JAK1-STAT3 Pathway.Current issues in molecular biology · 2025Article
- Modeling the extension of ovarian function after therapeutic targeting of the primordial follicle reserve.Human reproduction update · 2025Review
- The Final Phases of Ovarian Aging: A Tale of Diverging Functional Trajectories.Journal of clinical medicine · 2025Review
- Decreased FTO Expression Promotes Ovarian Granulosa Cells Aging.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Exploration of the mechanism and therapy of ovarian aging by targeting cellular senescence.Life medicine · 2025Review
- Dietary exposure to di(2-ethylhexyl) phthalate for 6 months alters markers of female reproductive aging in mice†.Biology of reproduction · 2025Article
- Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management.Frontiers in reproductive health · 2025Review
- Pharmacological effects and mechanisms of medicine food homology species and active ingredients in ameliorating ovarian aging.Frontiers in nutrition · 2025Review
- The therapeutic effects of ovarian stromal stem cells in the natural ovarian aging process in rats.Iranian journal of veterinary research · 2025Article
- Ovarian aging: pathophysiology and recent developments in maintaining ovarian reserve.Frontiers in endocrinology · 2025Review
- Phospholipid Phosphatase 3 (Cells · 2024Article
- Epigallocatechin-3-gallate improves the quality of maternally aged oocytes.Cell proliferation · 2024Article
- Progestin and adipoQ receptor 7 (PAQR7) mediate the anti-apoptotic effect of P4 on human granulosa cells and its deficiency reduces ovarian function in female mice.Journal of ovarian research · 2024Article
- Differential analysis of ovarian tissue between high and low-yielded laying hens in the late laying stage and the effect of LECT2 gene on follicular granulosa cells proliferation.Molecular biology reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging has been regarded as a treatable condition, and delaying aging could prevent some diseases. Ovarian aging, a special type of organ senescence, is the earliest-aging organ, as ovaries exhibit an accelerated rate of aging with characteristics of gradual declines in ovarian follicle quantity and quality since birth, compared to other organs. Ovarian aging is considered as the pacemaker of female body aging, which drives the aging of multiple organs of the body. Hence, anti-ovarian aging has become a research topic broadly interesting to both biomedical scientists and pharmaceutical industry. A marked progress has been made in exploration of possible anti-ovarian agents or approaches, such as calorie restriction mimetics, antioxidants, autophagy inducers etc., over the past years. This review is attempted to discuss recent advances in the area of anti-ovarian aging pharmacology and to offer new insights into our better understanding of molecular mechanisms underlying ovarian aging, which might be informative for future prevention and treatment of ovarian aging and its related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.